TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Serum HBV DNA readings less than 400 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal alanine aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dopamine release in the ventral striatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Grip force control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specimen size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of lymph nodes collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time of bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in the practical image-acquisition test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in the written retention test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean symptom complex severity score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean treatment outcome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of the prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decrease in triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incident diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for additional IOP lowering medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complication rate (Diplopia)
Endpoint domain: Adverse events/effects
Primary endpoint: Serum adiponectin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Jebsen Taylor test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrist and hand subportion of the Fugl‐Meyer arm motor scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active movement of the 2nd metacarpophalangeal joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful cecal retroflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth of ileal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nocturnal hypoglycemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: HbA(1c) <7.0%
Endpoint domain: Physiological/clinical
Primary endpoint: spinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median PFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical benefit response (CBR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of AAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-report measures of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Tactile thresholds greater than 0.5 g
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Discriminability less than 0.50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Forced-choice scores less than 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean time to relapse
Endpoint domain: Mortality/survival
Primary endpoint: 24-h proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AC failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower levels of fear at follow-up testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertigo score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Middle cerebral artery mean velocity (MCA Vm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vertebral artery mean velocity (VA Vm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain-free walking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ambulatory ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: S-phase fraction ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: momentary negative affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: complete necrosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: plasma DHA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum NFL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time to flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time to first bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: surgical hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Quality of care ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in the number of obstructive apnea events/hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in lowest oxygen saturation during REM sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lower limb discomfort improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mood parameters (valance and activation)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improved nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in all cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in all deaths
Endpoint domain: Mortality/survival
Primary endpoint: Midfacial recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regained sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Facial skin temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Facial swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recruitment efficiency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: satisfactory clinical outcome (cure or improvement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eradication of pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset of binge drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) (Maximum Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of inadequate health literacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of marginal health literacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tubular C4d staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: chronic allograft damage index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of vecuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time of vecuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thymus size recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean difference in ThCTnS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in ThCTkS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hair regrowth score (RGS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of remaining free of complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for additional help with medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Side effects rate
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom reduction in PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom reduction in depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal seal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microleakage values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients requiring oral narcotics or intravenous pain medication
Endpoint domain: Adverse events/effects
Primary endpoint: Recall of risk information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Recall of benefit information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean number of days in OBOT
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: overall performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV transmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median lesion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sensitivity of diagnostic findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of diagnostic findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eosinophil number decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ECP level decrease in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in lung function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to symptomatic progression
Endpoint domain: Mortality/survival
Primary endpoint: Time to opiate use for cancer pain
Endpoint domain: Mortality/survival
Primary endpoint: acceptable pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall health and quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cognitive function score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Social function score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Postoperative independence (SAP)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Epworth sleepiness scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Sleep apnoea quality of life index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Usage of auto-CPAP vs fixed-CPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secretory IgA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gram-negative aerobic flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lactobacillus spp in gut flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Arterial-blood lactate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Arterial-blood pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival to discharge from hospital
Endpoint domain: Mortality/survival
Primary endpoint: Median peak aspartate transaminase after transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Early allograft dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of progression to advanced AMD
Endpoint domain: Mortality/survival
Primary endpoint: True positive ETT results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False positive ETT results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypertensive haemodynamic response during ETT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Body movements associated with discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year all-cause mortality or non-fatal Q-wave myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Change in UACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in glucose variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: response rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: cooperation rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Augmented GH secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increased GH responses to low-dose ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Regular patterns of acylated ghrelin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Gastrointestinal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Reoperation for mediastinal hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: COX-2 protein expression in dysplastic epithelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: COX-2-positive interstitial cells frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Knee extensor torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cure ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defaulter ratios
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Forearm vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cognitive performance impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to adverse outcomes (death, non-fatal myocardial infarction, or non-fatal stroke)
Endpoint domain: Mortality/survival
Primary endpoint: serum ferritin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum TfR concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: leg stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain intensity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of opioid-free subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute coronary syndrome events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: type 1 myocardial infarction (MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: large myocardial infarctions with serum troponin >100× upper limit of normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Completion rate of interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: WOMAC function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dyspnoea scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hepatic steatosis incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: distance covered during the 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: FRAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: post-exercise hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: white matter hyperintensity volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ventricle volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Corneal sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal fluorescein staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of global psychological effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive symptoms of schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Negative symptoms of schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: frequency and severity of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Negative tests for sensory neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage change in Forced Expiratory Volume during first second (FEV(1))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Normalization of serum alanine aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Decrease in histological activity index score greater than 2 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Emergence of HBV mutants resistant to entecavir
Endpoint domain: Adverse events/effects
Primary endpoint: Movement during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of lumbar epidural venous puncture
Endpoint domain: Adverse events/effects
Primary endpoint: Time to next visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total white blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lymphocyte levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: improvement in symptoms and function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: drop in SSD scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in anger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in interpersonal functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in intima-media thickness of the common carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC((0‐t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0‐‐>t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0‐‐>infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basal sphincter of Oddi pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Phasic contraction frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: septic-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone Mineral Density (BMD) at femoral sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Jump height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alliance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: motivation for treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: perceived joint pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status